News
Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy
ENA101 targets DARKFOX®, a novel, cancer‑specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using Enara’s proprietary EDAPT® platform and represents a new class of highly tumor‑specific targets derived from the dark proteome.
Enara Bio enters 2026 with Dark Antigen licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies
Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T-cell engagers for solid tumors, today announced that Boehringer Ingelheim has exercised its option to license multiple additional Dark Antigen targets discovered and validated through the collaboration with Enara
All News
Browse our full news archives
Upcoming & Recent Events
Discover the events that the Enara Bio team are attending
AACR Annual Meeting 2026
San Diego, CaliforniaJ.P. Morgan Healthcare Conference
San Francisco, CaliforniaJefferies Global Healthcare Conference
London, UK40th SITC Annual Meeting
National Harbor, Maryland, USAASCO Annual Meeting
Chicago, IllinoisBio€quity Europe
Brugge, Belgium3rd Annual Dark Genome Symposium
New York, USA